We are very happy to announce that Professor Roland Andersson from Lund University will join the ApoGlyx Board of Directors!

He has served on the board of numerous biotech companies, most recently in the role of Chairman at Reccan Diagnostics. He adds vast combined academic and entrepreneurial experience to the board,...

ApoGlyx has applied for two patents covering Aquaporin-9 inhibitor technology. A first patent has been granted in the USA in 2018, and in 2020 in Australia, China, and Japan. A second patent has also been granted in the USA in August 2020.